clinical trial · NCT07802834
Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC
EGFRLung Cancer (NSCLC)Non Small Cell Lung CancerZipalertinib
brief summary
This study will evaluate the novel, oral EGFR TKI, zipalertinib, in the adjuvant ctDNA-adapted treatment of stage IA2 to IIIC atypical EGFR-mutant NSCLC after completion of definitive therapy with a primary endpoint of molecular response in participants identified as having minimal residual disease (MRD).
started
Nov 1, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Sep 3, 2026
official title
Adjuvant ctDNA-Adapted Personalized Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol